About

GI Dynamics Press Release - June 03, 2009

< Back to Press Releases

GI Dynamics’ EndoBarrier™ Gastrointestinal Liner to be Highlighted at Several Prominent International Diabetes and Obesity Meetings

Lexington, Mass., June 3, 2009 – GI Dynamics, a leader in non-surgical, endoscopic approaches for the treatment of type 2 diabetes and obesity, today announced that its EndoBarrier Gastrointestinal Liner will be highlighted by leading experts in metabolic disorders and endoscopy at several international diabetes and obesity meetings.

“This is proving to be a very successful year for GI Dynamics and our development efforts in support of the EndoBarrier,” said Stuart A. Randle, chief executive officer of GI Dynamics. “Based on the data we have seen to date, we believe EndoBarrier, as part of a multidisciplinary approach, has the potential to dramatically change the treatment paradigm for type 2 diabetes and weight problems due to its unique profile as a non-surgical and non-pharmaceutical treatment option. Notably, EndoBarrier may provide the benefits of gastric bypass surgery without the complications and risks associated with a highly invasive procedure, and unlike traditional pharmaceutical approaches, our implantable device removes the burden of dose regimen compliance from the patient.”

Recent & Upcoming Events:

  • Digestive Disease Week (DDW) 2009 from May 30-June 4, 2009 at McCormick Place in Chicago, Illinois
  • 69th Scientific Sessions of the American Diabetes Association (ADA) from June 5-9, 2009 at Morial Convention Center in New Orleans, Louisiana
  • Annual Meeting of the Endocrine Society (ENDO) 2009 on June 13, 2009 at the Walter E. Washington Convention Center in Washington, D.C.:  Lee M. Kaplan, M.D., Ph.D., associate professor of medicine, Harvard Medical School and director, MGH Weight Center, Massachusetts General Hospital, and Caroline Apovian, M.D., FACN, director, Nutrition and Weight Management Center, and co-director of Nutrition and Metabolic Support Service, Boston University Medical Center - both members of the company’s scientific advisory board - will be participating in a panel titled “The Role of the Gut in Obesity & Diabetes.” Dr. Kaplan will focus on endoscopic approaches for the treatment of diabetes and obesity, including the EndoBarrier, and Dr. Apovian will focus on perioperative management of the bariatric surgery patient, underscoring the need for a multidisciplinary approach to patient management.
  • European Society of Gastrointestinal Endoscopy (ESGE), Gastroenterology and Endotherapy: 27th European Workshop, June 22-24, 2009, Brussels Exhibition Centre in Brussels, Belgium: The EndoBarrier will be discussed during the “Endoluminal Surgery” afternoon session in a presentation titled “State of the Art Lecture: Duodeno-Jejunal Sleeve (Video)” on June 22, 2009  by Richard I. Rothstein, M.D., section chief, Gastroenterology and Hepatology and professor of medicine at the Dartmouth-Hitchcock Medical Center/Dartmouth Medical School.

About the EndoBarrier Gastrointestinal Liner

The patented EndoBarrier Gastrointestinal Liner is an advanced investigational, non-surgical medical device based on the EndoBarrier Technology platform for treating type 2 diabetes and obesity. The EndoBarrier Gastrointestinal Liner is placed in the GI tract endoscopically (via the mouth) to create a barrier between food and the wall of the intestine. Physicians believe that preventing food from coming into contact with the intestinal wall may alter the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery. A growing body of pre-clinical and clinical evidence supports the potential for EndoBarrier Gastrointestinal Liner to dramatically change the treatment landscape for people living with type 2 diabetes, obese people at risk for type 2 diabetes, and people with severe weight problems.

About GI Dynamics

GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for people combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarrier™ Gastrointestinal Liner, an advanced device in the EndoBarrier portfolio, may provide rapid improvement in glycemic control and significant weight loss by modifying metabolic pathways. 

The company is also developing the EndoBarrier Flow Restrictor, which is designed to further enhance the effectiveness of the liner by doubling the amount of weight-loss that can be achieved using the liner alone. Each device in the EndoBarrier portfolio is designed to assist patients gain control of their blood sugar and achieve a healthier body mass index (BMI). GI Dynamics is collaborating with experts in endocrinology, gastroenterology, bariatric surgery and medical weight loss on these efforts.

Based in Lexington, Massachusetts and founded in 2003, GI Dynamics is backed by top-tier investors including Advanced Technology Ventures, Catalyst Health Ventures, Cutlass Capital, Domain Associates, Johnson & Johnson Development Corporation, and Polaris Venture Partners. For more information, visit GI Dynamics online at www.gidynamics.com.

###